FDA says it needs a lit­tle more time to de­cide on Mer­ck­'s P2X3 for chron­ic cough

A few months ago, Mer­ck emerged as a clear leader among a group of drug­mak­ers rac­ing through the clin­ic with a new class of ther­a­pies for chron­ic cough. But it looks like the Ke­nil­worth, NJ-based phar­ma will now be tak­ing an­oth­er lap.

The FDA is de­lay­ing its de­ci­sion on Mer­ck’s gefapix­ant by at least a few months to “pro­vide time for a full re­view of the sub­mis­sion,” the com­pa­ny re­vealed in an SEC fil­ing. The agency, which orig­i­nal­ly set a PDU­FA date for Dec. 21, now ex­pects to make a de­ci­sion by March 21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER